Published in Gene Therapy Weekly, April 8th, 1996
The vaccine is being developed by Apollon Inc., Malvern, Pennsylvania. The firm is developing similar vaccines against HIV, human papilloma virus (HPV), hepatitis B virus, and human T-cell receptors (TCRs) for use in autoimmune disease. Two of the vaccines (HIV and TCR) are already in Phase I clinical trials.
Some 40 to 50 percent of U.S. residents are infected with HSV, according to Apollon researcher Catherine J. Pachuk. These infections result in 100 million cases of oral/labial herpes eruptions each year.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.